These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 22682812)

  • 1. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
    Palma DA; Senan S; Tsujino K; Barriger RB; Rengan R; Moreno M; Bradley JD; Kim TH; Ramella S; Marks LB; De Petris L; Stitt L; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):444-50. PubMed ID: 22682812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.
    Palma DA; Senan S; Oberije C; Belderbos J; de Dios NR; Bradley JD; Barriger RB; Moreno-Jiménez M; Kim TH; Ramella S; Everitt S; Rengan R; Marks LB; De Ruyck K; Warner A; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):690-6. PubMed ID: 24035329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
    Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
    Wang L; Wu S; Ou G; Bi N; Li W; Ren H; Cao J; Liang J; Li J; Zhou Z; Lv J; Zhang X
    Lung Cancer; 2012 Jul; 77(1):89-96. PubMed ID: 22418243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
    Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
    Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ; Belani CP; Khuri FR; Ramalingam SS
    JAMA Oncol; 2017 Aug; 3(8):1120-1129. PubMed ID: 27978552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
    Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
    Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
    Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
    Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
    Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy.
    Willner J; Jost A; Baier K; Flentje M
    Strahlenther Onkol; 2003 Aug; 179(8):548-56. PubMed ID: 14509954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
    Dang J; Li G; Zang S; Zhang S; Yao L
    Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
    Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of HL301 In Radiation Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Receiving Curative Concurrent Chemoradiotherapy: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2a Clinical Trial.
    Kim KH; Kang N; Song SY; Kim HJ; Kim YS; Oh MJ; Cho J
    Int J Radiat Oncol Biol Phys; 2024 Oct; 120(2):432-438. PubMed ID: 38565405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
    Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T
    Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
    J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
    Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer.
    Guilbault C; Garant A; Faria S; Owen S; Ofiara L; Duclos M; Hirsh V; Kopek N
    Clin Lung Cancer; 2017 Sep; 18(5):565-571. PubMed ID: 28344046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
    Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
    Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.